Logo
x

Search

Subscribe Now

gilead

Gilead Reports Data from the P-III (ASSURE) Trial of Seladelpar for Treating Primary Biliary Cholangitis

Gilead Reports Data from the P-III (ASSURE) Trial of Seladelpar for Treating Primary Biliary Cholangitis

  • June 5, 2024
The US FDA Approves the Label Update of Gilead’s Biktarvy for Pregnant Adults with HIV

The US FDA Approves the Label Update of Gilead’s Biktarvy for Pregnant Adults with HIV

  • April 29, 2024
Gilead Reports the US FDA’s Approval of sNDA for Vemlidy to Treat Hepatitis B Virus (HBV) Infection

Gilead Reports the US FDA’s Approval of sNDA for Vemlidy to Treat Hepatitis B Virus (HBV) Infection

  • April 1, 2024
Gilead and Xilio Therapeutics Join Forces to Develop XTX301 for the Treatment of Cancers

Gilead and Xilio Therapeutics Join Forces to Develop XTX301 for the Treatment of Cancers

  • March 29, 2024
Gilead and Merck Report Results from the P-II Clinical Evaluation of Islatravir + Lenacapavir for HIV

Gilead and Merck Report Results from the P-II Clinical Evaluation of Islatravir + Lenacapavir for HIV

  • March 7, 2024
Gilead and Compugen Sign an Exclusive License Agreement to Develop COM503, a Novel Pre-Clinical Immunotherapy Program

Gilead and Compugen Sign an Exclusive License Agreement to Develop COM503, a Novel Pre-Clinical Immunotherapy Program

  • December 20, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.